Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer ; volume:16 ; number:1 ; day:30 ; month:8 ; year:2016 ; pages:1-8 ; date:12.2016
BMC cancer ; 16, Heft 1 (30.8.2016), 1-8, 12.2016
- Urheber
-
Chen, Chin-Yau
- Beteiligte Personen und Organisationen
-
Yang, Chih-Yung
Chen, Yen-Chung
Shih, Chia-Wen
Lo, Su-Shun
Lin, Chi-Hung
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2681-7
- URN
-
urn:nbn:de:1111-201609281176
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Chin-Yau
- Yang, Chih-Yung
- Chen, Yen-Chung
- Shih, Chia-Wen
- Lo, Su-Shun
- Lin, Chi-Hung
- SpringerLink (Online service)
Ähnliche Objekte (12)
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma